col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


54 Results       Page 1

 [1] 
Elsevier: Cytokine & Growth Factor Reviews
  original article Date Title Authors   All Authors
1 [GO] 2023―Dec―09 COVID-19: from emerging variants to vaccination Thilini H. Senevirathne, Demi Wekking, Joseph W.R. Swain, Cinzia Solinas, Pushpamali De Silva
2 [GO] 2023―Nov―30 The impact of COVID-19 on cancer patients Demi Wekking, Thilini H. Senevirathne, Josie L. Pearce, Marco Aiello, Mario Scartozzi, Matteo Lambertini, et al. (+2)
3 [GO] 2023―Mar―05 Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron Lidong Wang, Michelle Møhlenberg, Pengfei Wang, Hao Zhou
4 [GO] 2022―Oct―13 Pharmacological therapies and drug development targeting SARS-CoV-2 infection Yizhou Jiang, Limor Rubin, Zhiwei Zhou, Haibo Zhang, Qiaozhu Su, Sheng-Tao Hou, et al. (+2)
5 [GO] 2022―Jul―07 Clinical progress in MSC-based therapies for the management of severe COVID-19 Maria Rossello-Gelabert, Ainhoa Gonzalez-Pujana, Manoli Igartua, Edorta Santos-Vizcaino, Rosa Maria Hernandez
6 [GO] 2022―Feb―12 The Coronavirus Pandemic - 2022: Viruses, Variants & Vaccines Magdalini Alexandridi, Julija Mazej, Enrico Palermo, John Hiscott
7 [GO] 2022―Jan―31 Roles of the Gut Microbiota in Severe SARS-CoV-2 Infection Yiran Liu, Dan Kuang, Dan Li, Ju Yang, Jiai Yan, Yanping Xia, et al. (+2)
8 [GO] 2022―Jan―13 Current utilization of interferon alpha for the treatment of coronavirus disease 2019: a comprehensive review Ling-Ying Lu, Po-Hao Feng, Ming-Sun Yu, Min-Chi Chen, Alex Jia-Hong Lin, Justin L. Chen, Lennex Hsueh-Lin Yu
9 [GO] 2022―Jan―08 Before the “cytokine storm”: boosting efferocytosis as an effective strategy against SARS-CoV-2 infection and associated complications Somit Dutta, Amartya Mukherjee, Upendra Nongthomba
10 [GO] 2021―Dec―16 EXPLOITING NATURAL ANTIVIRAL IMMUNITY FOR THE CONTROL OF PANDEMICS: LESSONS FROM COVID-19 Eleonora Aricò, Laura Bracci, Luciano Castiello, Francesca Urbani, Jean-Laurent Casanova, Filippo Belardelli
11 [GO] 2021―Nov―15 SARS-CoV-2 infection and oxidative stress: Pathophysiological insight into thrombosis and therapeutic opportunities Mohammad Shah Alam, Daniel M. Czajkowsky
12 [GO] 2021―Oct―25 Cancer and Covid-19: Collectively Catastrophic M du Plessis, C Fourie, J Riedemann, WJS de Villiers, AM Engelbrecht
13 [GO] 2021―Oct―25 Role of SARS-CoV-2 -induced cytokines and growth factors in coagulopathy and thromboembolism Firdos Ahmad, Meganathan Kannan, Abdul W. Ansari
14 [GO] 2021―Oct―22 COVID-19 and dys-regulation of pulmonary endothelium: implications of vascular remodeling Pavitra K. Jadaun, Suvro Chatterjee
15 [GO] 2021―Oct―19 S100A8/A9 in COVID-19 pathogenesis: Impact on clinical outcomes Leah Mellett, Shabaana A. Khader
16 [GO] 2021―Aug―02 ORF8a as a viroporin in SARS-CoV-2 infection? Milad Zandi
17 [GO] 2021―Jul―02 THE MOST RECENT SARS-CoV-2 MUTATIONS AND THEIR SUBSEQUENT VIRAL VARIANTS Begum Cosar, Zeynep Yagmur Karagulleoglu, Sinan Unal, Ahmet Turan Ince, Dilruba Beyza Uncuoglu, Gizem Tuncer, et al. (+16)
18 [GO] 2021―Jun―18 The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies Ni Zhao, Bin Di, Li-li Xu
19 [GO] 2021―Apr―15 COVID-19 as a Mediator of Interferon Deficiency and Hyperinflammation: Rationale for the Use of JAK1/2 Inhibitors in Combination with Interferon H.C. Hasselbalch, V. Skov, L. Kjær, C. Ellervik, A. Poulsen, T.D. Poulsen, C.H. Nielsen
20 [GO] 2021―Feb―21 SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders Amruta Narayanappa, Wesley H. Chastain, Meshi Paz, Rebecca J. Solch, Isabel C. Murray-Brown, Jaime B. Befeler, et al. (+4)
21 [GO] 2021―Feb―10 Type I and III IFN-mediated antiviral actions counteracted by SARS-CoV-2 proteins and host inherited factors Jorge Quarleri, M. Victoria Delpino
22 [GO] 2021―Jan―29 Interferons and other cytokines, genetics and beyond in COVID-19 and autoimmunity Ghislain Opdenakker, Jo Van Damme
23 [GO] 2021―Jan―12 The Cytokine storm in COVID-19: Further advances in our understanding the role of specific chemokines involved Francesca Coperchini, Luca Chiovato, Gianluca Ricci, Laura Croce, Flavia Magri, Mario Rotondi
24 [GO] 2020―Dec―16 Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy Inês Barros, António Silva, Luís Pereira de Almeida, Catarina Oliveira Miranda
25 [GO] 2020―Dec―13 The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy Jing Li, Bin Liu
26 [GO] 2020―Dec―01 SARS-CoV-2: targeted managements and vaccine development Moiz Bakhiet, Sebastien Taurin
27 [GO] 2020―Nov―05 Covid-19 in Brazil: A sad scenario Pedro Rafael D. Marinho, Gauss M. Cordeiro, Hemílio F.C. Coelho, Simone Cristina S. Brandão
28 [GO] 2020―Nov―04 Oncolytic Viral Immunotherapy in the Time of COVID-19 David Olagnier, Tommy Alain
29 [GO] 2020―Oct―23 A Clinical Trial of IL-15 and IL-21 Combination Therapy For COVID-19 Is Warranted Stephen W. Wilz
30 [GO] 2020―Oct―09 Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19 Hamed Fouladseresht, Mehrnoosh Doroudchi, Najmeh Rokhtabnak, Hossein Abdolrahimzadehfard, Amir Roudgari, Golnar Sabetian, Shahram Paydar
31 [GO] 2020―Oct―08 Type I IFN-dependent antibody response at the basis of sex dimorphism in the outcome of COVID-19 Lucia Gabriele, Alessandra Fragale, Giulia Romagnoli, Stefania Parlato, Caterina Lapenta, Stefano Maria Santini, et al. (+2)
32 [GO] 2020―Sep―21 Is Toll-like receptor 4 involved in the severity of COVID-19 pathology in patients with cardiometabolic comorbidities? Simone Cristina Soares Brandão, Júlia de Oliveira Xavier Ramos, Luca Terracini Dompieri, Emmanuelle Tenório Albuquerque Madruga Godoi, José Luiz Figueiredo, Emanuel Sávio Cavalcanti Sarinho, et al. (+2)
33 [GO] 2020―Sep―09 AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm Sebastiano Gangemi, Alessandro Tonacci
34 [GO] 2020―Aug―25 Cytokine storm with rapidly elevated interleukin-6 indicates sudden death in patients with critical COVID-19 Zhigang Hu, Sijia Li, Xinyu Song
35 [GO] 2020―Aug―25 Glycogen synthase kinase-3: A putative target to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic Anil Kumar Rana, Shubham Nilkanth Rahmatkar, Amit Kumar, Damanpreet Singh
36 [GO] 2020―Jul―18 Response to: Letter to the Editor on “Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev” by Eugenia Quiros-Roldan, Giorgio Biasiotto and Isabella Zanella Francesco Prattichizzo, Massimiliano Bonafè, Angelica Giuliani, Andrea Costantini, Gianluca Storci, Jacopo Sabbatinelli, Fabiola Olivieri
37 [GO] 2020―Jul―04 Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic? Eleonora Aricò, Laura Bracci, Luciano Castiello, Sandra Gessani, Filippo Belardelli
38 [GO] 2020―Jul―01 Cytokine Storm in COVID-19 patients transforms to a Cytokine Super Cyclone in patients with risk factors Betcy Susan Johnson, Malini Laloraya
39 [GO] 2020―Jun―24 A critical evaluation of glucocorticoids in the treatment of severe COVID-19 Cinzia Solinas, Laura Perra, Marco Aiello, Edoardo Migliori, Nicola Petrosillo
40 [GO] 2020―Jun―20 Overview of the COVID-19 and JAK/STAT Pathway Inhibition: Ruxolitinib Perspective Bakiye Goker Bagca, Cigir Biray Avci
41 [GO] 2020―Jun―11 Should we unstress SARS-CoV-2 infected cells? Fabiana Csukasi, Gustavo Rico, Jose Becerra, Ivan Duran
42 [GO] 2020―Jun―07 COVID-19 infection may increase the risk of parkinsonism - Remember the Spanish flu? Mohamed A. Eldeeb, Faraz S. Hussain, Zaeem A. Siddiqi
43 [GO] 2020―Jun―06 IL-15 immunotherapy is a viable strategy for COVID-19 Hemanth Kumar Kandikattu, Sathisha Upparahalli Venkateshaiah, Sandeep Kumar, Anil Mishra
44 [GO] 2020―Jun―04 Letter to the Editor on “Bonafè M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev” Eugenia Quiros-Roldan, Giorgio Biasiotto, Isabella Zanella
45 [GO] 2020―Jun―02 SARS-CoV-2 infection: The role of cytokines in COVID-19 disease Víctor J. Costela-Ruiz, Rebeca Illescas-Montes, Jose M. Puerta-Puerta, Concepción Ruiz, Lucia Melguizo-Rodríguez
46 [GO] 2020―May―28 The global impact of the coronavirus pandemic John Hiscott, Magdalini Alexandridi, Michela Muscolini, Evelyne Tassone, Enrico Palermo, Maria Soultsioti, Alessandra Zevini
47 [GO] 2020―May―20 IL-6: relevance for immunopathology of SARS-CoV-2 E.O. Gubernatorova, E.A. Gorshkova, A.I. Polinova, M.D. Drutskaya
48 [GO] 2020―May―20 Acute inflammation and pathogenesis of SARS-CoV-2 infection: Cannabidiol as a potential anti-inflammatory treatment? Cecilia T. Costiniuk, Mohammad-Ali Jenabian
49 [GO] 2020―May―13 The Covid-19 pandemic in Denmark: Big lessons from a small country David Olagnier, Trine H. Mogensen
50 [GO] 2020―May―11 The Cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system Francesca Coperchini, Luca Chiovato, Laura Croce, Flavia Magri, Mario Rotondi
51 [GO] 2020―May―07 COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons Shivraj Hariram Nile, Arti Nile, Jiayin Qiu, Lin Li, Xu Jia, Guoyin Kai
52 [GO] 2020―May―06 Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients Begum Dariya, Ganji Purnachandra Nagaraju
53 [GO] 2020―May―04 Inflamm-aging: Why older men are the most susceptible to SARS-CoV-2 complicated outcomes Massimiliano Bonafè, Francesco Prattichizzo, Angelica Giuliani, Gianluca Storci, Jacopo Sabbatinelli, Fabiola Olivieri
54 [GO] 2020―Apr―25 Cytokine storm intervention in the early stages of COVID-19 pneumonia Xinjuan Sun, Tianyuan Wang, Dayong Cai, Zhiwei Hu, Jin’an Chen, Hui Liao, et al. (+6)
 [1] 

54 Results       Page 1



[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.025 sec